1 reports of this reaction
50.0% of all ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR reports
#2 most reported adverse reaction
DISEASE RECURRENCE is the #2 most commonly reported adverse reaction for ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR, manufactured by Haleon US Holdings LLC. There are 1 FDA adverse event reports linking ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR to DISEASE RECURRENCE. This represents approximately 50.0% of all 2 adverse event reports for this drug.
Patients taking ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR who experience disease recurrence should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DISEASE RECURRENCE is a frequently reported adverse event for ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR, accounting for a significant proportion of all reports.
In addition to disease recurrence, the following adverse reactions have been reported for ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR:
The following drugs have also been linked to disease recurrence in FDA adverse event reports:
DISEASE RECURRENCE has been reported as an adverse event in 1 FDA reports for ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR. This does not prove causation, but indicates an association observed in post-market surveillance data.
DISEASE RECURRENCE accounts for approximately 50.0% of all adverse event reports for ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR, making it one of the most commonly reported side effect.
If you experience disease recurrence while taking ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.